Brief: Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure
16/06/2025 14:11
June 16 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: UNIT ENTERED INTO A LICENSE AGREEMENT WITH NEXTCURE PURSUANT TO LICENSE AGREEMENT, GROUP ELIGIBLE TO RECEIVE PAYMENTS UP TO US$745 MILLION UNDER DEAL NEXTCURE TO OBTAIN GLOBAL RIGHTS TO SIM0505 NOVEL ANTIBODY-DRUG CONJUGATE, OTHERS Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660